Tag
A novel nomogram using pretransplant triglycerides and body weight shows promise to guide early mycophenolate mofetil dosing after kidney transplantation, potentially reducing drug overexposure before therapeutic drug monitoring is feasible
This review synthesizes clinical evidence on busulfan pharmacokinetics, highlighting the critical role of TDM, the impact of body weight normalization, and significant drug interactions with deferasirox.
This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.
A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.
A large-scale multinational study reveals that meropenem and piperacillin dosing during renal replacement therapy must be tailored to RRT intensity and urine output, with extended infusions significantly improving therapeutic target attainm
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuation
First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr
A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.
Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.
Dihydroberberine demonstrates superior absorption compared to berberine, suggesting enhanced pharmacological properties. Recent studies highlight its potential in metabolic and inflammatory diseases, warranting further clinical exploration.
This review synthesizes the latest 5-year evidence on dihydroberberine, highlighting improved bioavailability over berberine, mechanistic insights from metabolic and network pharmacology studies, and its promising clinical applications in m
Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.
Exploring why certain medications start with a larger first dose, the clinical evidence, common misconceptions, and practical guidelines for safe use.
